Axiom Biosciences Investigates Stem Cell Delivery for Medical Applications
1 report, 1 independent
Updated Sep 28
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Axiom Biosciences is currently researching stem cell delivery for various medical applications. The company focuses on delivery mechanisms including stem cells, nanoparticles, messenger RNA, and fusion proteins. The majority of Axiom’s pipeline utilizes mesenchymal stem cells (MSCs) sourced from Wharton’s jelly, a substance found in the umbilical cord.
From sdbj.com
Why it matters
Axiom founder and CEO Dr. Remo Moomiaie-Qajar noted that the company's work aims to achieve targeted delivery to specific tissues or organs. The primary indications for these MSCs are intraventricular hemorrhage in newborns and hypoxic ischemic encephalopathy. This research contrasts with the typical decade-long, billion-dollar process for a single novel drug.
From sdbj.com